We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Stem Cells From Unfertilized Female Eggs

By Biotechdaily staff writers
Posted on 27 Oct 2004
For the first time in clinical literature, researchers have reported that cells derived from an unfertilized female egg can be transformed into multipurpose stem cells. More...
The finding was presented at the annual Clinical Congress of the American College of Surgeons (ACS) in New Orleans (LA, USA) in October 2004.

The researchers believe that parthenogenesis, the ability to created a cloned embryo from an egg with it being fertilized, may be an alternative source of stem cells that would not require human embryonic tissue. The stem cells obtained by this method, however, would not necessarily be a substitute for embryonic stem cells.

"One would never want to say that one cell type is going to be a replacement for another,” pointed out Dr. Anthony Atala, professor of surgery and director of the Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine (Winston Salem, NC, USA). "The different cell types are different options for the future. Some cell types are going to have pluses and others are going to have minuses.”

A big advantage of stem cells obtained through parthenogenesis is that they may be used in the same patient without immunosuppression therapy. In contrast, human embryonic stem cells would be immunologically different from the patient being treated and therefore the cells would be rejected unless the patient underwent immunosuppression.

"A woman produces an egg every 28 days. Unless it is fertilized, the egg is discarded. We may be able to take that egg, grow cells needed for a particular kind of therapy, and deliver them back to the patient,” explained Dr. Atala. " Since the cells would be genetically matched to the patient, they would not be rejected and immunnosuppression would not be needed.”

It is not yet clear how parthenogenesis-derived cells may be applied clinically. "We're looking at conditions that need cells for therapy,” said Dr. Atala. "The hope is that for any condition that requires cell or tissue therapy, this technology would have potential implications.”

In the study, the investigators took eggs from rabbits and activated them with electrical energy to induce cell division. Once a mass of cells was generated within the egg, the researchers removed them and grew them in culture. Cells that had specific markers consistent with the ability to transform into different cell lines were selected. These cells then were treated with growth factors to differentiate them into muscle, blood vessels, bone, and fat. Results showed that sufficient numbers of cells could be produced for cell or tissue-engineering purposes.


Related Links:
Wake Forest U.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.